Margaret G. McGlynn's most recent trade in Novavax, Inc. was a trade of 28,326 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 28,326 | 28,326 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 18,884 | 18,884 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 10,420 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 10,420 | 25,588 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 74,872 | 74,872 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 20,414 | 91,550 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 15,630 | 15,630 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,420 | 10,420 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 10,470 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 0 | - | - | Restricted Stock Units | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 42,467 | 42,467 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 11,847 | 71,136 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 4.90 per share. | 31 Mar 2024 | 2,029 | 5,829 (0%) | 0% | 4.9 | 9,942 | Common Stock |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 8.61 per share. | 31 Mar 2024 | 1,178 | 15,168 (0%) | 0% | 8.6 | 10,143 | Common Stock |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 12.77 per share. | 31 Mar 2024 | 778 | 13,990 (0%) | 0% | 12.8 | 9,935 | Common Stock |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 13.93 per share. | 31 Mar 2024 | 713 | 13,212 (0%) | 0% | 13.9 | 9,932 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 7,500 | 7,500 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 13.40 per share. | 04 Mar 2024 | 7,500 | 59,289 (0%) | 0% | 13.4 | 100,500 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.80 per share. | 04 Mar 2024 | 7,500 | 66,789 (0%) | 0% | 2.8 | 21,000 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.80 per share. | 04 Mar 2024 | 7,500 | 66,789 (0%) | 0% | 2.8 | 21,000 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 13.29 per share. | 04 Mar 2024 | 7,500 | 59,289 (0%) | 0% | 13.3 | 99,675 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 7,500 | 0 | - | - | Stock Options (right to buy) | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2023 | 7,710 | 7,710 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2023 | 6,670 | 6,670 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 3,100 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 3,100 | 3,800 (0%) | 0% | - | Common Stock | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,474 | 30,474 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 8,584 | 59,289 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 3,481 | 3,481 | - | - | Stock Option (Right to Buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 13.03 per share. | 13 Jan 2023 | 15,000 | 50,705 (0%) | 0% | 13.0 | 195,387 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.32 per share. | 13 Jan 2023 | 15,000 | 65,705 (0%) | 0% | 3.3 | 49,800 | Common Stock |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 700 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 700 | 700 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,600 | 4,600 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 3,100 | 3,100 | - | - | Restricted Stock Units | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,423 | 45,423 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,671 | 50,705 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 02 May 2022 | 15,000 | 38,034 (0%) | 0% | 7.0 | 104,897 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 May 2022 | 15,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.79 per share. | 02 May 2022 | 15,000 | 53,034 (0%) | 0% | 4.8 | 71,850 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 4,462 | 4,462 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 May 2022 | 921 | 178 (0%) | 0% | - | Common Stock | |
| Vertex Pharma | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 921 | 5,609 | - | - | Deferred Stock Units | |
| Vertex Pharma | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2022 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.54 per share. | 08 Apr 2022 | 5,000 | 6,099 (0%) | 0% | 127.5 | 637,700 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 280.19 per share. | 08 Apr 2022 | 4,900 | 1,199 (0%) | 0% | 280.2 | 1,372,931 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 281.49 per share. | 08 Apr 2022 | 100 | 1,099 (0%) | 0% | 281.5 | 28,149 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 5,000 | 10,000 | - | - | Common Stock (right to buy) | |
| Vertex Pharma | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.54 per share. | 31 Mar 2022 | 5,000 | 6,099 (0%) | 0% | 127.5 | 637,700 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 262.37 per share. | 31 Mar 2022 | 2,970 | 2,110 (0%) | 0% | 262.4 | 779,239 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 261.28 per share. | 31 Mar 2022 | 1,019 | 5,080 (0%) | 0% | 261.3 | 266,244 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 262.97 per share. | 31 Mar 2022 | 1,011 | 1,099 (0%) | 0% | 263.0 | 265,863 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 127.54 per share. | 28 Jan 2022 | 5,000 | 6,099 (0%) | 0% | 127.5 | 637,700 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2022 | 5,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 242.78 per share. | 28 Jan 2022 | 2,087 | 1,311 (0%) | 0% | 242.8 | 506,682 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 240.53 per share. | 28 Jan 2022 | 1,901 | 4,198 (0%) | 0% | 240.5 | 457,248 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 241.83 per share. | 28 Jan 2022 | 800 | 3,398 (0%) | 0% | 241.8 | 193,464 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 243.24 per share. | 28 Jan 2022 | 212 | 1,099 (0%) | 0% | 243.2 | 51,567 | Common Stock |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 1,300 | 1,300 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 700 | 700 | - | - | Restricted Stock Units | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 36,111 | 36,111 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,115 | 38,034 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Margaret G. McGlynn | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jun 2021 | 699 | 1,099 (0%) | 0% | - | Common Stock | |
| Vertex Pharma | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 699 | 4,688 | - | - | Deferred Stock Units | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Sale of securities on an exchange or to another person at price $ 10.27 per share. | 03 May 2021 | 10,000 | 27,919 (0%) | 0% | 10.3 | 102,704 | Common Stock |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2021 | 10,000 | 0 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Margaret G. McGlynn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.51 per share. | 03 May 2021 | 10,000 | 37,919 (0%) | 0% | 7.5 | 75,100 | Common Stock |
| Vertex Pharma | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2021 | 3,034 | 3,034 | - | - | Stock Option (Right to Buy) | |
| Vertex Pharma | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2021 | 921 | 1,798 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2020 | 7,700 | 7,700 | - | - | Stock Option (Right to buy) | |
| Air Products & Chemicals | Margaret G. McGlynn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2020 | 194 | 42,813 | - | - | Phantom Stock |